The Peter Attia Drive

View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter's Weekly Newsletter
In this episode, Peter explores the complex and often misunderstood world of genetic testing, building a practical framework for understanding what these tests can and cannot actually tell us about health and disease. He explains why some genetic findings can be genuinely life-changing while many others offer information that is far more probabilistic than deterministic, and why directly measuring the phenotype is often more valuable than inferring risk from DNA alone. Peter examines where genetics can provide meaningful insight across the major disease categories and where its predictive power is far more limited than many people assume. He also discusses how to think critically about different types of genetic tests, how to interpret results in the proper context, and how to avoid the common trap of accumulating more genetic information without gaining greater clarity or actionable insight.
We discuss:
Genetic testing: understanding what it can reveal, where it falls short, and how to think about its clinical value [1:45];
The Human Genome Project: why decoding DNA did not immediately unlock the mysteries of disease [4:15];
The limitations of genetic testing: probabilistic risk, interpretive uncertainty, and the importance of phenotype [9:30];
Questions to ask when considering genetic testing [15:45];
Genetic testing in cardiovascular and metabolic disease: when genotype adds value beyond phenotype [17:00];
Genetic testing for inherited cardiac conditions: identifying hidden risk beyond routine screening [21:45];
Genetic testing for cancer risk: inherited syndromes, clinical utility, and the limits of consumer testing [24:00];
Genetic testing for neurodegenerative disease: risk prediction, planning, and the challenge of limited actionability [28:45];
Functional medicine genetic testing: the gap between biological plausibility and clinical evidence, and the supplement protocols that aren't supported by evidence [32:45];
Pharmacogenetics: using genetic testing to guide medication selection and safety [38:45];
A framework for evaluating genetic tests according to effect size and clinical actionability [41:45];
The major types of genetic tests, and how each should be matched to the clinical question being asked [43:30];
Interpreting genetic test results: choosing the right testing laboratory and understanding what the findings actually mean [49:45];
Framework summary: why genetic testing is most valuable when it is guided by a clear question, matched with the appropriate test, and capable of meaningfully influencing decisions [56:45]; and
More.
Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter's Weekly Newsletter
In this episode, Peter takes a deep dive into colorectal cancer (CRC) screening, explaining why it is one of the most preventable cancers and why getting screening right can have life-saving implications. He walks through how colorectal cancer develops and why it is uniquely well-suited to early detection and prevention, with a particular emphasis on the dual role of colonoscopy as both a diagnostic and therapeutic tool. Peter also examines the concerning rise in early-onset CRC among younger adults, highlighting why awareness and timely screening matter more than ever. The episode provides a practical guide to preparing for and evaluating the quality of a colonoscopy, including how to think about appropriate screening intervals and the real risks and tradeoffs involved. Finally, Peter explores the expanding landscape of non-invasive screening options, offering clear insight into what these alternatives can and cannot do so listeners can make informed decisions about their care at any age.
We discuss:
CRC statistics and goals for this episode [1:00];
Colorectal cancer development: polyp progression, risk types, and the window for prevention [4:00];
Why colorectal cancer is uniquely screenable: direct visualization and the dual role of colonoscopy [6:30];
Colonoscopy effectiveness: prevention through polyp removal and interpreting the NordICC trial data [8:15];
Rising colorectal cancer in younger adults: trends, possible causes, and the case for earlier screening [12:15];
Colonoscopy preparation: why bowel prep matters and how newer options improve the experience [16:45];
Colonoscopy quality, polyp miss rates, and personalized screening intervals [20:00];
Colonoscopy risks versus colorectal cancer risk: understanding the true risk-benefit tradeoff [29:30];
Non-invasive screening options for CRC: benefits, limitations, and their role alongside colonoscopy [37:00];
Colorectal cancer prevention principles: why screening matters and the role of colonoscopy [39:30]; and
More.
Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter's Weekly Newsletter
In this "Ask Me Anything" (AMA) episode, Peter answers listener questions across a wide range of topics, focusing on how to think through real-world trade-offs and apply scientific evidence in practice. He explores how to build and interpret a meaningful family health history, how individual risk tolerance influences decisions around testing and treatment, and why heart disease remains poorly prevented despite available tools. He also examines whether it's possible to carry excess body fat while remaining metabolically healthy, outlines the minimum effective dose for strength training for those with limited time, and discusses the habits and interventions most likely to reduce dementia risk. Additional topics include what evidence would need to emerge for him to reconsider his current stance on NAD-boosting supplements, and when hydration and electrolyte strategies are truly beneficial versus unnecessary.
If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #84 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.
We discuss:
Topics overview [1:15];
Using family history to assess disease risk: why it matters more than genetic testing and how to analyze it effectively [2:30];
Peter's views that differ from conventional medicine: approaches to cardiovascular risk, cancer screening, nutrition, and more [10:30];
Risk tolerance in health decisions: weighing action versus inaction and avoiding low-benefit, high-risk interventions [16:00];
Why cardiovascular disease persists: delayed treatment, insufficient thresholds, and missed opportunities for early intervention [22:00];
Whether someone can be overweight yet metabolically healthy, and how fat distribution influences metabolic risk [26:45];
Strength training with limited time: how to maximize results with intensity and efficiency [30:00];
Designing a sustainable exercise routine: balancing volume, recovery, and enjoyment over time [34:45];
Reducing dementia risk: prioritizing exercise, sleep, and cardiometabolic health based on individual gaps [38:00];
Peter's current skepticism toward NAD-related supplements and what evidence would be needed to change his view [40:45];
Hydration and electrolytes: factors that impact needs and when supplementation might be necessary [43:30]; and
More.
Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter's Weekly Newsletter
In this episode, Peter explores one of the most foundational topics underlying nearly everything discussed on the podcast: how to think scientifically. Framed as an introspective deep dive, he examines why scientific thinking is inherently difficult for humans, the cognitive biases and tendencies that make it challenging to separate belief from evidence, and why these challenges are even more consequential in today's environment saturated with misinformation. He also offers a framework for improving our ability to evaluate claims, question assumptions, and identify a personal panel of experts, providing listeners with practical tools to become more disciplined and effective thinkers.
We discuss:
Topics to be covered and goals for this episode [2:00];
Scientific thinking: hypotheses, uncertainty, and the process of ruling out explanations [3:45];
How scientific knowledge differs from mathematical proof: useful approximations, evolving evidence, and acting under uncertainty [8:00];
Why scientific thinking is difficult: evolution, social instincts, and the need for deliberate practice [13:30];
Systems and tools designed to correct human bias [18:15];
How to think scientifically pt. 1: Notice when you're feeling certain [20:30];
How to think scientifically pt. 2: Judge the process, not just the conclusion [23:00];
How to think scientifically pt. 3: Notice when identity is shaping your beliefs [28:15];
How to think scientifically pt. 4: Don't confuse criticism with understanding [33:45];
How to think scientifically pt. 5: Outsource your thinking carefully [36:15];
Evaluating who to trust: incentives, consensus, and red flags in scientific credibility [45:15];
Science as a self-correcting system: why updating with evidence is a strength, not a weakness [49:00];
The key principles of scientific thinking, and a practical framework for evaluating claims and improving judgment [50:45]; and
More.
Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter's Weekly Newsletter
In this episode, Peter takes a deep dive into prostate cancer screening, explaining why advanced and metastatic diagnoses continue to rise despite the availability of screening tools, and what can be done to reverse this trend. He breaks down what PSA actually measures and why it is far more informative when tracked over time rather than interpreted as a single value, and he explores how tools like MRI, PSA density, PSA velocity, and improved biopsy techniques can both reduce unnecessary procedures and improve the detection of aggressive cancers. Peter also discusses the role of active surveillance in avoiding overtreatment for low-risk cases, examines the flawed evidence that has historically been used to argue against PSA screening, and highlights how medications like finasteride can suppress PSA levels and potentially mask warning signs if not properly accounted for. Ultimately, he makes a compelling case for the importance of regular PSA testing as a key strategy in the effort to eliminate prostate cancer mortality.
We discuss:
The failure of current prostate cancer screening guidelines, and the rise in advanced disease despite available tools [2:30];
PSA screening fundamentals: benefits, harms, and the guideline shift driven by overdiagnosis concerns [5:30];
The impact of reduced PSA screening: rising rates of late-stage prostate cancer and worsening population-level outcomes [12:00];
How modern screening practices use PSA trends, MRI, and new imaging advances to improve accuracy and reduce unnecessary procedures [15:00];
Advances in prostate biopsy: transperineal approach improves safety and cancer detection [23:00];
Reducing overtreatment: Gleason scoring and active surveillance in modern prostate cancer care [25:30];
Reevaluating PSA screening guidelines: how flaws in the PLCO trial undermine the evidence used to argue against PSA screening [29:45];
Prostate cancer screening today: improved tools, flawed guidelines, and preventable mortality [33:45];
How finasteride and similar drugs suppress PSA levels and can lead to missed or delayed prostate cancer diagnoses if not properly accounted for [38:00];
The optimistic future of prostate cancer: modern screening advances and the potential to reduce mortality [43:15]; and
More.
Connect With Peter on Twitter, Instagram, Facebook and YouTube